in vitro News and Research

RSS

Synthon’s SYD985 ADC demonstrates anti-tumor activity, outperforms leading anti-HER2 ADC

Synthon Biopharmaceuticals today announced the results of a head-to-head comparative program of its antibody-drug conjugate (ADC) SYD985 with Roche's market leading anti-HER2 ADC, T-DM1 (Kadcyla).

2 Apr 2014

UM researchers awarded FDA contract to expand high-throughput sequencing database

Researchers at the Institute for Genome Sciences at the University of Maryland School of Medicine have been awarded a research program contract from the U.S. Food and Drug Administration (FDA) to sequence, assemble, and annotate a population of bacterial pathogens using two high-throughput sequencing (HTS) technologies in support of the expansion of a vetted public reference database.

2 Apr 2014

FDA approves ORALAIR sublingual allergy immunotherapy tablet

GREER Laboratories, Inc., a leading developer and provider of allergy immunotherapy products and services, today announced that the U.S. Food and Drug Administration has approved ORALAIR (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) sublingual allergy immunotherapy tablet.

2 Apr 2014

Neuropeptide receptors could provide treatment target for chemoresistant SCLC

The discovery of a novel broad spectrum neuropeptide antagonist, peptide–1, which is related to the substance P analogue SP-G, could help develop treatments targeted at chemoresistant small-cell lung cancer, indicate study results.

1 Apr 2014

Molecular function of "hairless" gene may contribute to pathogenesis of atrichia with papular lesions

It's not a hair-brained idea: A new research report appearing in the April 2014 issue of The FASEB Journal explains why people with a rare balding condition called "atrichia with papular lesions" lose their hair, and it identifies a strategy for reversing this hair loss.

1 Apr 2014

GIN and Sigolis merge to create new company, Ginolis Oy

Global Innovation Network Oy (GIN) and Sigolis AB today announced a merger of the two companies. The new company, named Ginolis Oy, provides an innovative one-stop solution for the development and manufacturing of in vitro diagnostic (IVD) disposable products.

1 Apr 2014

New research may open door to novel therapies for treating immune disorders

A new research discovery published in the April 2014 issue of the Journal of Leukocyte Biology may open the door to new therapies that help treat immune disorders or curb runaway inflammation. Specifically, scientists have discovered a molecule that can induce cell death (apoptosis) in a key type of immune cell (dendritic cells).

1 Apr 2014

Venaxis files 510(k) premarket submission with FDA for APPY1 Test

Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration.

31 Mar 2014

ATHENA develops surrogate organ system for toxicity testing

Creating surrogate human organs, coupled with insights from highly sensitive mass spectrometry technologies, a new project is on the brink of revolutionizing the way we screen new drugs and toxic agents.

29 Mar 2014

Scientists discover simple method to measure density of engineered nanoparticles in physiological fluids

Thousands of consumer products containing engineered nanoparticles — microscopic particles found in everyday items from cosmetics and clothing to building materials — enter the market every year. Concerns about possible environmental health and safety issues of these nano-enabled products continue to grow with scientists struggling to come up with fast, cheap, and easy-to-use cellular screening systems to determine possible hazards of vast libraries of engineered nanomaterials.

29 Mar 2014

'Mini heart' invented to aid blood flow through venous segments

George Washington University researcher Narine Sarvazyan, Ph.D., has invented a new organ to help return blood flow from veins lacking functional valves. A rhythmically contracting cuff made of cardiac muscle cells surrounds the vein acting as a 'mini heart' to aid blood flow through venous segments. The cuff can be made of a patient's own adult stem cells, eliminating the chance of implant rejection.

28 Mar 2014

Study: Guinea pigs and mice can be replaced with non-animal skin sensitization method

Guinea pigs and mice can be replaced with a non-animal skin sensitization method that uses a human-derived skin model, according to a study presented today by the PETA International Science Consortium, Ltd., at the Society of Toxicology's annual meeting.

27 Mar 2014

EKF Molecular to exhibit PointMan DNA-enrichment technology at AACR 2014

EKF Diagnostics, the global in vitro diagnostics business, will be present on Booth #438 at AACR 2014, 5-9th April, San Diego.

From EKF Diagnostics 26 Mar 2014

Peach extract prevents breast cancer metastasis in mice

Lab tests at Texas A&M AgriLife Research have shown that treatments with peach extract inhibit breast cancer metastasis in mice.

26 Mar 2014

Singulex signs agreement to co-develop the Sgx Clarity system with Tecan

Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC) technology for clinical diagnostics and scientific discovery, today announced an agreement to co-develop the Sgx Clarity system with Tecan, a leading global provider of laboratory automation instruments.

From Tecan 25 Mar 2014

Marina Cavazzana, Adrian J. Thrasher honored with Pioneer Award for gene therapy

Marina Cavazzana, MD, PhD, Paris Descartes University, France and Adrian J. Thrasher, MD, PhD, University College London Institute of Child Health, UK, have been honored with the Pioneer Award for basic and clinical gene therapy for immunodeficiency disorders.

25 Mar 2014

Researchers use retro approach to produce new drugs

This alternative approach to creating artificial organic molecules, called bioretrosynthesis, was first proposed four years ago by Brian Bachmann, associate professor of chemistry at Vanderbilt University. Now Bachmann and a team of collaborators report that they have succeeded in using the method to produce the HIV drug didanosine.

25 Mar 2014

CSP analogues may attenuate S. pneumoniae virulence, resistance

The spread of virulent, antibiotic-resistant strains of Streptococcus pneumoniae may be controllable through the use of competence-stimulating peptide analogues, US researchers believe.

24 Mar 2014

Systemic stem cell therapy reduces malignant mesothelioma growth

Systemic delivery of stem cells expressing an apoptosis-inducing protein can successfully incorporate into malignant pleural mesothelioma cells and subsequently induce their death, according to preclinical study findings.

19 Mar 2014

Findings open way to identification of new cancer drugs to fight acute myeloid leukemia

The Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal (UdeM), in collaboration with the Maisonneuve-Rosemont Hospital's Quebec Leukemia Cell Bank, recently achieved a significant breakthrough thanks to the laboratory growth of leukemic stem cells, which will speed up the development of new cancer drugs.

18 Mar 2014